Adverum Q1 net loss $24.8M; cash $193.3M; LUNA Phase 2 interim data to be presented in July

Adverum Biotechnologies, Inc.

2024-Q1 EPS reported -$1.50

Net loss of $24.8M ($1.50 per share) vs $29.1M in Q1 2023; R&D and G&A expenses decreased.
Cash, equivalents and short-term investments $193.3M as of March 31, 2024, up from $96.5M year-end; funds into late 2025.
LUNA Phase 2 interim analysis (26-week landmark) to be presented at ASRS July 17–20, 2024.
Preliminary LUNA data: 94% and 90% reduction in annualized anti-VEGF injections at 2E11 and 6E10 doses; 85% and 68% injection-free at 26 weeks.
Ixo-vec generally well tolerated; no serious adverse events, vasculitis, or vascular occlusion reported.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Adverum Biotechnologies, Inc. reported the quarter ended March 31, 2024 results: net income Net Loss was $24.8 million, or $1.50 per basic and diluted share, EPS $1.50 per basic and diluted share.

Period: the quarter ended March 31, 2024
Net income: Net Loss was $24.8 million, or $1.50 per basic and diluted share
EPS: $1.50 per basic and diluted share
Result: reported results

Exact text from the filing

Net Loss was $24.8 million, or $1.50 per basic and diluted share, for the three months ended March 31, 2024, compared to $29.1 million, or $2.90 per basic and diluted share for the same period in 2023.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001628280-24-022224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.